The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

Undiagnosed or untreated EPI could result in muscle loss since the patient isn’t absorbing the necessary nutrients.

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission.

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...

Eli Lilly just gave investors several reasons to cheer.

The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

Obesity and family practice experts share when it’s safe to prescribe GLP-1 receptor agonists to patients with thyroid ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally ...